Renaissance Capital’s October IPO Market Update The fourth quarter kicked off with 22 IPOs raising a combined $3.8 billion in the busiest month for new issuance in nearly three years, despite an end-of-month slowdown ahead of the US presidential election....read more
Three sizable IPOs priced this past week, joined by a flurry of small issuers and blank check companies. One scheduled deal did not get done (PRB). Tech distributor Ingram Micro (INGM) priced slightly above the midpoint to raise $409...read more
Septerna, a Phase 1 biotech targeting GPCRs in multiple therapeutic areas, raised $288 million by offering 16 million shares at $18, as expected. The company offered 0.7 million more shares than anticipated. It originally planned to offer 10.9 million shares at...read more
Septerna, a Phase 1 biotech targeting GPCRs in multiple therapeutic areas, raised the proposed deal size for its upcoming IPO on Thursday. The South San Francisco, CA-based company now plans to raise $275 million by offering 15.3 million shares at $18. The...read more
Renaissance Capital’s October IPO Market Update
Renaissance Capital’s October IPO Market Update The fourth quarter kicked off with 22 IPOs raising a combined $3.8 billion in the busiest month for new issuance in nearly three years, despite an end-of-month slowdown ahead of the US presidential election....read more
US IPO Weekly Recap: Sizable tech and biotech IPOs are joined by a flurry of small names
Three sizable IPOs priced this past week, joined by a flurry of small issuers and blank check companies. One scheduled deal did not get done (PRB). Tech distributor Ingram Micro (INGM) priced slightly above the midpoint to raise $409...read more
GPCR-focused biotech Septerna prices further upsized IPO at $18
Septerna, a Phase 1 biotech targeting GPCRs in multiple therapeutic areas, raised $288 million by offering 16 million shares at $18, as expected. The company offered 0.7 million more shares than anticipated. It originally planned to offer 10.9 million shares at...read more
GPCR-focused biotech Septerna ups proposed deal size by 57% ahead of $275 million IPO
Septerna, a Phase 1 biotech targeting GPCRs in multiple therapeutic areas, raised the proposed deal size for its upcoming IPO on Thursday. The South San Francisco, CA-based company now plans to raise $275 million by offering 15.3 million shares at $18. The...read more